Skip to main content
. 2019 Nov 4;20(21):5481. doi: 10.3390/ijms20215481

Figure 3.

Figure 3

Safety profiling of PCIII in vivo. (A) The body weights of mice treated with high dose PCIII (i.p., 10 mg/kg/day) or DMSO vehicle for 7 days. (B) The spontaneous exploration of mice treated with high dose PCIII or DMSO traced by the open field test (left panel). The blue box is a center area, and the red box is a periphery area. The area inside of the red box is “Center+Periphery” zone, and the area outside of the red box is “Border” zone. The total distance traveled by mice treated with DMSO or high dose PCIII during the 15-min session (n = 4 per group, right panel). (C) Relative anxiety was assessed by comparing the time and distance spent between the center and periphery of the open field arena (n = 4 mice per group). (D) Motor coordination of the mice treated with high dose PCIII or DMSO determined by rotarod test (n = 4 mice per group). (E) Assessment of potential bradykinesia determined by the pole test (n = 4 mice per group). The quantified data are expressed as means ± SEMs. Statistical significance was determined by unpaired two tailed student t-test test, NS, nonsignificant.